Preoperative Serum CEA and CA19-9 in Gastric Cancer - a Single Tertiary Hospital Study of 1,075 Cases

  • Zhou, Yang-Chun (Division of Gastrointestinal Surgery, Department of General Surgery, First Affiliated Hospital, Nanjing Medical University) ;
  • Zhao, Hai-Jian (Division of Gastrointestinal Surgery, Department of General Surgery, First Affiliated Hospital, Nanjing Medical University) ;
  • Shen, Li-Zong (Division of Gastrointestinal Surgery, Department of General Surgery, First Affiliated Hospital, Nanjing Medical University)
  • Published : 2015.04.14


To evaluate the clinical impact of preoperative serum CEA and CA19-9 on resectable gastric cancer (GC), a total of 1,075 consecutive cases with gastric adenocarcinoma were obtained retrospectively from January 2012 and December 2013 in a single tertiary hospital, and the relationships between serum CEA, CA19-9 and clinicopathologic features were investigated. Positive preoperative serum rates of CEA and CA19-9 were 22.4% and 12.3% respectively, levels significantly correlating with each other and depth of invasion, lymph node involvement, pTNM and stage. The CEA level also presented a remarkable association with lymphovascular invasion. Both CEA and CA19-9 positivity significantly and positively correlated with depth of invasion, nodal involvement, pTNM stage, lymphovascular invasion, tumor size and tumor location. Stratified analyses according to gender or tumor location showed preoperative CEA or CA19-9 had different associations with clinicopathologic features in different gender subgroups or location subgroups. Preoperative serum CA19-9 positivity may be more meaningful for tumor size rather than CEA. In conclusion, preoperative serum CEA and CA19-9 correlate with disease progression of GC, and may have applications in aiding more accurate estimation of tumor stage, decision of treatment choice and prognosis evaluation.


Gastric cancer;tumor markers;CEA, CA19-9;clinicopathologic feature


Supported by : National Natural Science Foundation of China


  1. Basbug M, Arikanoglu Z, Bulbuller N, et al (2011) . Prognostic value of preoperative CEA and CA 19-9 levels in patients with colorectal cancer. Hepatogastroenterol, 58, 400-405.
  2. Chen XZ, Jiang K, Hu JK, et al (2008) . Cost-effectiveness analysis of chemotherapy for advanced gastric cancer in China. World J Gastroenterol, 14, 2715-2722.
  3. Choi SR, Jang JS, Lee JH, et al (2006) . Role of serum tumor markers in monitoring for recurrence of gastric cancer following radical gastrectomy. Dig Dis Sci, 51, 2081-6.
  4. Dilege E, Mihmanli M, Demir U, et al (2010) . Prognostic value of preoperative CEA and CA 19-9 levels in resectable gastric cancer. Hepatogastroenterol, 57, 674-7.
  5. Duffy MJ (2007). Role of tumor markers in patients with solid cancers: a critical review. Eur J Intern Med, 18, 175-84.
  6. Fan B, Xiong B (2011). Investigation of serum tumor markers in the diagnosis of gastric cancer. Hepatogastroenterol, 58, 239-45.
  7. Gold P, Freedman SO (1965). Specific carcinoembryonic antigens of the human digestive system. J Exp Med, 122, 467-81.
  8. Han ES, Lee HH, Lee JS, et al (2014). At which stage of gastric cancer progression do levels of carcinoembryonic antigen and carbohydrate antigen 19-9 increase? application in advanced gastric cancer treatment. J Gastric Cancer, 14, 123-8.
  9. Huang ZB, Zhou X, Xu J, et al (2014) . Prognostic value of preoperative serum tumor markers in gastric cancer. World J Clin Oncol, 5, 170-6.
  10. Humphris JL, Chang DK, Johns AL, et al (2012) . The prognostic and predictive value of serum CA19.9 in pancreatic cancer. Ann Oncol, 23, 1713-22.
  11. Ikeda Y, Oomori H, Koyanagi N, et al (1995). Prognostic value of combination assays for CEA and CA 19-9 in gastric cancer. Oncol, 52, 483-486.
  12. Jemal A, Bray F, Center MM, et al (2011). Global Cancer Statistics. Ca Cancer J Clin, 61, 69-90.
  13. Lee JC, Lee SY, Kim CY, et al (2013). Clinical utility of tumor marker cutoff ratio and a combination scoring system of preoperative carcinoembryonic antigen, carbohydrate antigen 19-9, carbohydrate antigen 72-4 levels in gastric cancer. J Korean Surg Soc, 85, 283-289.
  14. Li F, Li S, Wei L, et al (2013). The correlation between pre-operative serum tumor markers and lymph node metastasis in gastric cancer patients undergoing curative treatment. Biomarkers, 18, 632-7.
  15. Liu X, Cai H, Wang Y (2012). Prognostic significance of tumor markers in T4a gastric cancer. World J Surg Oncol, 10, 68.
  16. Marrelli D, Roviello F, De Stefano A, et al (1999) . Prognostic significance of CEA, CA 19-9 and CA 72-4 preoperative serum levels in gastric carcinoma. Oncol, 57, 55-62.
  17. Marrelli D, Pinto E, De Stefano A, et al (2001). Preoperative positivity of serum tumor markers is a strong predictor of hematogenous recurrence of gastric cancer. J Surg Oncol, 78, 253-8.
  18. Mattar R, Alves de Andrade CR, DiFavero GM, et al (2002). Preoperative serum levels of CA 72-4, CEA, CA 19-9, and alpha-fetoprotein in patients with gastric cancer. Rev Hosp Clin Fac Med Sao Paulo, 57, 89-92.
  19. Park SH, Ku KB, Chung HY, et al (2008). Prognostic significance of serum and tissue carcinoembryonic antigen in patients with gastric adenocarcinomas. Cancer Res Treat, 40, 16-21.
  20. Polat E, Duman U, Duman M, et al (2014) . Preoperative serum tumor marker levels in gastric cancer. Pak J Med Sci, 30, 145-149.
  21. Sakamoto J, Nakazato H, Teramukai S, et al (1996). Association between preoperative plasma CEA levels and the prognosis of gastric cancer following curative resection. tumor marker committee, japanese foundation for multidisciplinary treatment of cancer, Tokyo, Japan. Surg Oncol, 5, 133-9.
  22. Seregni E, Ferrari L, Martinetti A, et al (2001). Diagnostic and prognostic tumor markers in the gastrointestinal tract. Semin Surg Oncol, 20, 147-66.
  23. Shimada H, Noie T, Ohashi M, et al (2014). Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the task force of the japanese gastric cancer association. Gastric Cancer, 17, 26-33.
  24. Sikaroodi M, Galachiantz Y, Baranova A (2010). Tumor markers: the potential of "omics" approach. Curr Mol Med, 10, 249-57.
  25. Tian SB, Yu JC, Kang WM, et al (2014). Combined detection of CEA, CA 19-9, CA 242 and CA 50 in the diagnosis and prognosis of resectable gastric cancer. Asian Pac J Cancer Prev, 15, 6295-300.
  26. Ucar E, Semerci E, Ustun H, et al (2008) . Prognostic value of preoperative CEA, CA 19-9, CA 72-4, and AFP levels in gastric cancer. Adv Ther, 25, 1075-1084.
  27. Victorzon M, Haglund C, Lundin J, et al (1995). A prognostic value of CA 19-9 but not of CEA in patients with gastric cancer. Eur J Surg Oncol, 21, 379-84.
  28. Xiao J, He X, Wang Z, et al (2014). Serum carbohydrate antigen 19-9 and prognosis of patients with gastric cancer. Tumour Biol, 35, 1331-4.
  29. Ychou M, Duffour J, Kramar A, et al (2000). Clinical significance and prognostic value of CA72-4 compared with CEA and CA19-9 in patients with gastric cancer. Dis Markers, 16, 105-10.

Cited by

  1. Relationship of Amplification and Expression of the C-MYC Gene with Survival among Gastric Cancer Patients vol.16, pp.16, 2015,
  2. Clinicopathological features and prognosis of gastric cancer in young patients vol.16, pp.1, 2016,
  3. Blood type AB predicts promising prognosis in gastric cancer patients with positive preoperative serum CEA vol.96, pp.47, 2017,
  4. Genome-wide long non-coding RNAs identified a panel of novel plasma biomarkers for gastric cancer diagnosis pp.1436-3305, 2019,